Innocan Pharma’s BI Sky Global Hits Major Sales Milestone and Passes Key Safety Test

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) has something to celebrate. Its subsidiary, BI Sky Global, just completed a crucial safety test while also smashing a major sales milestone. The company’s progress signals strong momentum in the growing personal care and wellness market.

HRIPT Testing Confirms Product Safety

BI Sky Global successfully passed the Human Repeated Insult Patch Test (HRIPT), a gold-standard evaluation for determining the irritation and sensitization potential of cosmetic products. This test is critical for consumer safety, ensuring that products meet regulatory requirements before they hit the market.

The HRIPT is widely used in the personal care industry to assess skin reactions over time. It involves repeated applications of a product on test subjects’ skin to check for any adverse reactions. Passing this test means BI Sky Global’s products meet safety standards for widespread consumer use.

“Successfully completing HRIPT testing is a major step forward in reinforcing our commitment to high-quality, safe products,” said Roni Kamhi, CEO of BI Sky Global.

Sales Surge to 5,000 Units Per Day

Beyond safety, BI Sky Global is proving its commercial strength with a sales milestone that stands out in the industry. The company has surpassed an average of 5,000 units sold per day in 2024.

For perspective:

  • Most cosmetic brands manufacture a total of 5,000 units for an entire production run.
  • BI Sky Global sells that amount daily.
  • This pace puts the company ahead of many competitors, strengthening its manufacturing and distribution partnerships.

Kamhi highlighted the importance of this achievement: “This positions us very well for further expansion in sales and marketing as we capitalize on our success.”

Scaling Up and Market Impact

With strong sales numbers, BI Sky Global is well-positioned for aggressive expansion. Large-scale production and distribution deals become easier to negotiate when a brand demonstrates consistent demand.

This level of sales also suggests a growing consumer base, a key indicator that BI Sky Global’s products are resonating with the market. Investors and stakeholders will likely view this milestone as a signal of financial stability and growth potential.

Iris Bincovich, CEO of Innocan Pharma, emphasized the bigger picture: “This is further clear evidence of how the strength of our subsidiary BI Sky Global’s operations is delivering great value to our shareholders.”

Innocan’s Broader Vision

Innocan Pharma isn’t just focused on cosmetics. The company has made strides in pharmaceutical innovation, particularly in non-opioid pain management. Its CBD-loaded liposome drug delivery platform is designed to offer controlled and prolonged CBD release, an area with strong demand as the world looks for alternatives to traditional pain relief.

Meanwhile, the company’s wellness segment continues to expand through BI Sky Global, which focuses on high-performance self-care and beauty products. With a robust online sales strategy, BI Sky Global has positioned itself as a leader in direct-to-consumer wellness retail.

What’s Next?

With the safety testing hurdle cleared and sales exceeding expectations, BI Sky Global has plenty of momentum heading into the rest of 2025. The next steps will likely include:

  • Expanding distribution to new regions.
  • Strengthening partnerships with third-party manufacturers.
  • Scaling production to keep up with demand.

If these trends continue, BI Sky Global could become a dominant force in the personal care and wellness space. For now, Innocan Pharma and its subsidiary have every reason to celebrate their latest achievements.

Leave a Reply

Your email address will not be published. Required fields are marked *